DendrouCAFuggerLFrieseMA.Immunopathology of multiple sclerosis. Nat Rev Immunol2015; 15: 545–558.
2.
MagliozziRHowellOWReevesCet al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol2010; 68: 477–493.
3.
ThompsonAJBanwellBLBarkhofFet al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
4.
MagliozziRHowellOWNicholasRet al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol2018; 83: 739–755.
5.
AbsintaMVuoloLRaoAet al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology2015; 85: 18–28.
6.
ZivadinovRRamasamyDPVaneckovaMet al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Mult Scler2017; 23(10): 1336–1345.
7.
HarrisonDMWangKYFiolJet al. Leptomeningeal enhancement at 7T in multiple sclerosis: Frequency, morphology, and relationship to cortical volume. J Neuroimaging2017; 27: 461–468.
8.
MakshakovGMagonovETotolyanNet al. Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple Sclerosis. Neurol Res Int2017; 2017: 8652463.
9.
ZivadinovRRamasamyDPHagemeierJet al. Evaluation of leptomeningeal contrast enhancement using pre-and postcontrast subtraction 3D-FLAIR imaging in multiple sclerosis. AJNR Am J Neuroradiol2018; 39: 642–647.
10.
AbsintaMCorteseICVuoloLet al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology2017; 88: 1439–1444.
